Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:JNJNASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$157.42+2.3%$159.49$140.68▼$169.99$379.37B0.497.95 million shs10.97 million shsNVAXNovavax$6.00-3.2%$7.27$3.90▼$23.86$965.06M3.158.26 million shs4.87 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson0.00%+3.83%-3.38%+7.07%+8.74%NVAXNovavax0.00%+2.39%-22.28%-28.57%+54.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJNJJohnson & Johnson4.5084 of 5 stars2.35.04.23.93.32.50.6NVAXNovavax3.5843 of 5 stars3.22.00.04.72.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJNJJohnson & Johnson 2.56Moderate Buy$171.829.15% UpsideNVAXNovavax 2.43Hold$18.00200.00% UpsideCurrent Analyst Ratings BreakdownLatest NVAX and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.004/16/2025JNJJohnson & JohnsonSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform4/16/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.004/16/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$164.00 ➝ $169.004/14/2025JNJJohnson & JohnsonRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$165.00 ➝ $162.004/10/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$171.00 ➝ $159.004/9/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$163.00 ➝ $164.004/9/2025JNJJohnson & JohnsonThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$157.00 ➝ $172.004/2/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.004/2/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral2/28/2025NVAXNovavaxBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.00(Data available from 4/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJNJJohnson & Johnson$88.82B4.27$12.94 per share12.17$29.69 per share5.30NVAXNovavax$682.16M1.41N/AN/A($6.04) per share-0.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJNJJohnson & Johnson$14.07B$6.6523.6714.222.5618.20%34.24%13.63%N/ANVAXNovavax-$545.06M-$1.33N/A75.002.85-32.18%N/A-17.05%5/9/2025 (Estimated)Latest NVAX and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025NVAXNovavax$0.19N/AN/AN/A$204.08 millionN/A4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion2/27/2025Q4 2024NVAXNovavax-$0.75-$0.51+$0.24-$0.51$85.48 million$88.31 million1/22/2025Q4 2024JNJJohnson & Johnson$1.99$2.04+$0.05$1.41$22.44 billion$22.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJNJJohnson & Johnson$4.963.15%+5.43%74.59%63 YearsNVAXNovavaxN/AN/AN/AN/AN/ALatest NVAX and JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJNJJohnson & Johnson0.431.110.86NVAXNovavaxN/A0.930.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJNJJohnson & Johnson69.55%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipJNJJohnson & Johnson0.16%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJNJJohnson & Johnson152,7002.41 billion2.40 billionOptionableNVAXNovavax1,990160.84 million158.58 millionOptionableNVAX and JNJ HeadlinesRecent News About These CompaniesWhat is Zacks Research's Forecast for Novavax Q1 Earnings?April 19 at 6:53 AM | marketbeat.comZacks Research Has Bearish Estimate for Novavax Q1 EarningsApril 19 at 1:51 AM | americanbankingnews.comNovavax Sees Unusually Large Options Volume (NASDAQ:NVAX)April 18 at 1:57 PM | marketbeat.comFY2027 EPS Estimates for Novavax Lowered by Zacks ResearchApril 18 at 8:57 AM | marketbeat.comZacks Research Reduces Earnings Estimates for NovavaxApril 18 at 4:39 AM | americanbankingnews.comRenaissance Technologies LLC Has $11.32 Million Holdings in Novavax, Inc. (NASDAQ:NVAX)April 18 at 3:51 AM | marketbeat.comBank of America Securities Keeps Their Hold Rating on Novavax (NVAX)April 17 at 5:48 PM | markets.businessinsider.comNovavax (NasdaqGS:NVAX) Study Shows Reduced Symptoms With New COVID-19 Vaccine FormulaApril 17 at 12:30 AM | finance.yahoo.comPromising Results from Novavax’s SHIELD-Utah Study Boost Buy Rating Amid Vaccine Market DynamicsApril 16, 2025 | tipranks.comHere's Why Novavax (NVAX) Fell More Than Broader MarketApril 15, 2025 | zacks.comSHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms ...April 15, 2025 | gurufocus.comNovavax (NVAX) COVID-19 Vaccine Shows Lower Reactogenicity in SHIELD Study | BNTX Stock NewsApril 15, 2025 | gurufocus.comSHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNAApril 15, 2025 | prnewswire.comShares plunge after RFK Jr questions Novavax approachApril 14, 2025 | thepharmaletter.comQuinn Opportunity Partners LLC Acquires 125,000 Shares of Novavax, Inc. (NASDAQ:NVAX)April 14, 2025 | marketbeat.comNovavax (NVAX) Stock Plunges Amid Approval DelayApril 13, 2025 | gurufocus.comTrexquant Investment LP Sells 516,572 Shares of Novavax, Inc. (NASDAQ:NVAX)April 13, 2025 | marketbeat.comTraders Buy High Volume of Novavax Call Options (NASDAQ:NVAX)April 12, 2025 | americanbankingnews.comNVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 JabApril 11, 2025 | zacks.comNovavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowApril 11, 2025 | zacks.comNovavax says ‘no official response’ from FDA on BLA status for COVID shotApril 11, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?Are Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatSigns of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? By Chris Markoch | April 16, 2025View Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? NVAX and JNJ Company DescriptionsJohnson & Johnson NYSE:JNJ$157.42 +3.51 (+2.28%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$157.50 +0.08 (+0.05%) As of 04/17/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Novavax NASDAQ:NVAX$6.00 -0.20 (-3.23%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$5.98 -0.02 (-0.33%) As of 04/17/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/14 - 04/18 Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
